These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35596983)

  • 21. Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.
    Pfaller MA; Flamm RK; Jones RN; Farrell DJ; Mendes RE
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5393-9. PubMed ID: 27353270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer.
    Rolston KVI; Reitzel R; Vargas-Cruz N; Shelburne SA; Raad II; Prince RA
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):351-353. PubMed ID: 29661529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting.
    Abad L; Tafani V; Tasse J; Josse J; Chidiac C; Lustig S; Ferry T; Diot A; Laurent F; Valour F
    J Antimicrob Chemother; 2019 Mar; 74(3):625-632. PubMed ID: 30517641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China.
    Liu H; Wang Y; Liu N; Zhao L
    Indian J Med Microbiol; 2015 Feb; 33 Suppl():164-5. PubMed ID: 25657144
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.
    Zhang H; Hua W; Lin S; Zhang Y; Chen X; Wang S; Chen J; Zhang W
    Infect Drug Resist; 2022; 15():4845-4852. PubMed ID: 36045871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
    Deshpande D; Srivastava S; Nuermberger E; Koeuth T; Martin KR; Cirrincione KN; Lee PS; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S342-S348. PubMed ID: 30496456
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Brown-Elliott BA; Wallace RJ
    J Clin Microbiol; 2017 Jun; 55(6):1747-1754. PubMed ID: 28330892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
    Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
    Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative activity of tedizolid against clinical isolates of linezolid-resistant coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus.
    Pérez-Parra S; Peña-Monje A; Recio JL; García-García F
    Enferm Infecc Microbiol Clin; 2017 May; 35(5):323-324. PubMed ID: 27743684
    [No Abstract]   [Full Text] [Related]  

  • 31. In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates.
    Prammananan T; Chaiprasert A; Leechawengwongs M
    Int J Antimicrob Agents; 2009 Feb; 33(2):190-1. PubMed ID: 18945598
    [No Abstract]   [Full Text] [Related]  

  • 32. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
    J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates.
    Tato M; de la Pedrosa EG; Cantón R; Gómez-García I; Fortún J; Martín-Davila P; Baquero F; Gomez-Mampaso E
    Int J Antimicrob Agents; 2006 Jul; 28(1):75-8. PubMed ID: 16774814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.
    Wasserman S; Louw G; Ramangoaela L; Barber G; Hayes C; Omar SV; Maartens G; Barry C; Song T; Meintjes G
    J Antimicrob Chemother; 2019 Aug; 74(8):2377-2384. PubMed ID: 31081017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
    Yang M; Zhan S; Fu L; Wang Y; Zhang P; Deng G
    Drug Discov Ther; 2022 May; 16(2):99-101. PubMed ID: 35418550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of tedizolid and other comparator drugs in methicillin-resistant Staphylococcus aureus isolates in skin and soft tissue infections in seven Colombian hospitals.
    Leal AL; Ovalle MV; Cortés JA; Montañes AM; De la Rosa ZR; Rodríguez JY; Gualtero S; Ariza B; Sussman O; Torres MDP
    Biomedica; 2018 Dec; 38(4):507-513. PubMed ID: 30653864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of tedizolid against linezolid-resistant staphylococci and enterococci.
    Silva-Del Toro SL; Greenwood-Quaintance KE; Patel R
    Diagn Microbiol Infect Dis; 2016 May; 85(1):102-4. PubMed ID: 26971179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
    Zhang Z; Pang Y; Wang Y; Liu C; Zhao Y
    Int J Antimicrob Agents; 2014 Mar; 43(3):231-5. PubMed ID: 24439458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
    Richter E; Rüsch-Gerdes S; Hillemann D
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1534-6. PubMed ID: 17242139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.